spacer
home > epc > spring 2009 > competing with big pharma
PUBLICATIONS
European Pharmaceutical Contractor

Competing with Big Pharma

Good ideas for new drugs can come from anywhere. There was a time – now it seems like ancient history – when virtually all ideas came from the R&D departments of large pharmaceutical companies. Today, they often come from research carried out by dedicated groups of scientists at universities and small and medium-sized biotech firms, or even ‘virtual’ research groups connected by the internet.

Regardless of how it’s achieved, coming up with a concept for a new drug is not a random event. It starts with deciding what questions to ask in order to identify potential targets for a disease, and later focuses on developing strategies to find effective candidates that selectively affect those targets. Through hard work and trial and error, thousands of labs across the UK are developing new candidates every day. Thankfully, with some regularity, one scientist will turn to his or her colleagues and say, “I think we’ve got something here.” Then what?


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Mark Crane joined Ricerca as Vice President, Business Development and Marketing in June 2007. Mark has overseen the development of the new Ricerca ‘IP to IND’ brand, as well as the development of the website and sales literature. Prior to joining Ricerca, Mark served as Vice President, Sales and Marketing, for both Bridge Global Pharmaceutical Services and Quest Pharmaceutical Services. Mark was also a Vice President, of Global Business Development, Preclinical/Discovery Services for MDS Pharmaceutical Services, and held various posts at MDS Panlabs, AVANTEC, Inc and the Perkin Elmer Corporation. He holds a BS degree in Health Education/Community Health from Western Connecticut State University at Danbury.

spacer
Mark Crane
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Migration safe pharmaceutical labels improve patient safety

UPM Raflatac

Labels play an invaluable role on pharmaceutical packages. Pharmaceutical companies should only use labels that meet low-leachability and extraction requirements. Labels that are not migration safe, e.g. create leachable chemical compounds, may fail testing and result in significant launch delays or costly recalls. This white paper presents how pharmaceutical companies can ensure that the final label constructions achieve their business, regulatory and patient safety goals.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement